Tauzin Expected To Leave House For Trade Group
Lawmaker Declined Hollywood Job
http://www.washingtonpost.com/wp-dyn/articles/A42531-2004Jan23.html?nav=hptoc_pBy Frank Ahrens
Washington Post Staff Writer
Saturday, January 24, 2004; Page E01
Rep. W.J. "Billy" Tauzin (R-La.) is close to a decision to leave Congress to head the pharmaceutical industry's trade association after turning down an offer from Hollywood to succeed Jack Valenti as the movie industry's top lobbyist, sources in Washington and California said yesterday.
Tauzin telephoned Valenti with his decision late Thursday night after intense salary negotiations over recent days. The 12-term lawmaker is now considering an offer from the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group that represents drug giants such as Pfizer Inc. and Merck & Co.
Tauzin chairs the House Energy and Commerce Committee, which oversees the telecommunications, media and entertainment industries. Most recently, however, he was one of the principal authors of the Medicare prescription drug bill that included several provisions expected to vastly expand the market for prescription drugs among the elderly. In addition to adding hundreds of billions of dollars for drug benefits, the law bars the federal government from directly bargaining down the price of drugs, a provision PhRMA pressed for.
PhRMA made a run at Tauzin in recent days and offered a compensation package that, if Tauzin accepts it, "would be the biggest deal given to anyone at a trade association," a source said. The organization recently announced that current president Alan F. Holmer will retire once a successor is appointed, following an ultimately successful but image-punishing battle over the Medicare legislation.
Tauzin would not be the first key public official involved in the Medicare legislation to leave for the private sector. In December, Thomas A. Scully, an author of the bill, resigned as administrator of the Centers for Medicare and Medicaid Services, part of the Department of Health and Human Services, to join an Atlanta law firm that represents drugmakers, hospitals and other health-care businesses.